Genferon light
Genferon light (interferon alpha + taurine) is an immunomodulator used for the treatment of influenza and other acute respiratory viral infections in children under 14 years of age and has a whole “bouquet” of pharmacological effects for this purpose, such as: antiviral, antibacterial, antiproliferative, anti-inflammatory, antioxidant, local regenerating and membrane stabilizing. Interferon alpha blocks the replication of viruses even at the stage of synthesis of specific proteins and prevents infection of “healthy” cells of the mucous membrane of the nasal cavity, which is the “entry gate” for viral invasion and the primary inflammatory focus in acute respiratory diseases. The immunomodulatory effect of the drug is expressed in the activation of cell-mediated immune reactions, which ensures an enhanced immune response against viruses and bacteria. The drug “inspires” killer T-cells, NK-cells and B-lymphocytes, increases the production of antibodies, stimulates phagocytosis and increases the likelihood of identification of affected cells by cells of the immune system. Activation of leukocytes located in all layers of the mucous membrane guarantees their active participation in the elimination of pathological foci. In addition, due to the pharmacological “passionarity” of interferon alpha, restoration of the synthesis of immunoglobulin A is achieved. The antibacterial effect of geneferon light is based on a pool of immune reactions catalyzed by interferon. The second component of Genferon Light - taurine - normalizes tissue metabolism and promotes faster regeneration of the mucous membrane of the nasal cavity affected by inflammation. With the intranasal (through the nose) route of administration of the drug, due to the high concentration of active substances in the infectious focus, it is possible to achieve a quick and fairly powerful local antiviral and immunomodulatory effect. Systemic absorption of the drug is very low: the low systemic bioavailability of intranasal Genferon Light is due to the presence in the mucous membrane of the nasal cavity of a special class of proteins, which are a kind of biological “doormen” and strictly control the movement of any molecular and cellular objects through the mucosa. Nevertheless, a certain amount of interferon penetrates into the systemic bloodstream, which suggests that geneferon light has a systemic immunostimulating effect.
When the drug is administered through the rectum, its high (over 80%) bioavailability is noted, which provides both local and systemic immunomodulatory effects. With the intravaginal (and there is such a) method of administration of the drug, due to the high concentration of active components in the infectious focus, a local antiviral, antibacterial and antiproliferative effect is achieved. As for the systemic effect, due to the extremely low absorption capacity of the vagina, it is practically absent.
Genferon light is available in three dosage forms: nasal drops, nasal spray and vaginal and rectal suppositories. Drop dosage regimen: children from 29 days to 11 months - 1 drop in both nasal passages 5 times a day, children from 1 to 3 years - 2 drops in both nasal passages 3-4 times a day, children from 3 to 14 years - 2 drops in both nasal passages 4-5 times a day. The duration of treatment is 5 days. After instillation, you should gently massage the wings of the nose with your fingers to evenly distribute the active substances in the nasal cavity. Spray dosing regimen: one dose (equivalent to one short press on the dispenser) into both nasal passages three times a day for 5 days. When in contact with a person with signs of acute respiratory viral infection or immediately after hypothermia, Genferon Light is administered one dose into each nasal passage for 5-7 days. If necessary, the medication course can be repeated. When spraying the spray, the aerosol can must be kept strictly in a vertical position. Suppository dosage regimen: adults and children aged 7 years and older are prescribed 250,000 IU of interferon alpha per suppository; children under 7 years old - 125,000 IU interferon alpha per suppository. The route of administration, dose and duration of the drug course depend on the age of the patient and the clinical picture of the disease. Genferon light fits well into complex treatment regimens for ARVI. In combination with antibacterial, antimycotic and other antiviral drugs, an increase in the effect of each drug is observed.
Genferon light Spray, 100 d, 50000 IU, nasal
Description
Genferon Light spray is the only antiviral nasal spray for the treatment and prevention of ARVI and influenza with a maximum dose of the active substance* for adults and children over 14 years of age.
Approved for use in pregnant women. Genferon Light spray - maximum 1 dose. Comfortable, modern, convenient.
Genferon Light is the only combination of interferon and taurine** in Russia for the treatment and prevention of ARVI and influenza. Tested in 9 large clinical studies on 1579 patients.
Advantages of the drug Genferon Light spray.
1. Actively fights viruses and bacteria at the site of their invasion - the nasal cavity.
2. Has a universal antiviral effect.
3. Activates protective local immunity.
4. Contains glycerol*****, known for its moisturizing properties***,****.
5. Contains mint oil*****
Advantages of the release form.
1. The dosed spray nozzle Genferon Light in the form of a spray ensures comfortable use and dose accuracy: 1 press - 1 dose of 50 thousand IU of the drug
2. Genferon Light in the form of a spray provides a fine (“fog-like”) spray of the drug to create an even distribution over the entire surface of the nasopharynx, helping to block viral invasion.
3. The special design of the bottle with a pump ensures full use of the antiviral agent without residue.
4. Cost-effectiveness of Genferon Light spray: one bottle of antiviral spray contains 100 doses. Can be used for several episodes of colds or for prevention throughout the cold season.
5. An opened bottle of Genferon Light can be used until the end of the drug’s shelf life.
6. Can be combined with other drugs (symptomatic, etiotropic).
7. The spray form is not characterized by stomach side effects typical of oral medications.
*The maximum dosage of IFN alpha 2b is 50,000 IU in 1 dose, among nasal interferons, according to the GRLS March 2021.
**According to GRLS data March 2021.
***Raymond KR et al. Handbook of pharmaceutical excipients. Sixth edition. 2009 (Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Handbook of Pharmaceutical Excipients. Sixth edition. 2009).
****Marie Loudin et al. Dermatology: Clinical and Basic Science Series. Dry skin and moisturizers. Second edition. 2006 (Marie Loden, Howard I. Maibach. Dermatology: Clinical&Basic science series. Dry skin and moisturizers. Chemistry and Function. Second edition. 2006).
*****Auxiliary component.
Description
Transparent colorless or light yellow liquid, without visible mechanical inclusions.
Genferon Light is an antiviral barrier and targeted activity precisely at the source of infection!
28.08.2019
OTCPHARM JSC informs partners, clients and consumers about the resumption of commercial shipments of the previously popular antiviral spray GENFERON® LIGHT .
GENFERON® LIGHT spray is a unique1 combined antiviral drug that provides the possibility of complex therapy, as well as prevention of the development of influenza and ARVI in adults, including pregnant women, as well as in children over 14 years of age.
The combination of two active components in one dosage form allows for a wider spectrum of action of GENFERON® LITE in comparison with other nasal forms of interferon presented on the Russian pharmaceutical market. In addition, the presence of taurine in the composition helps to preserve the biological activity of interferon and enhance the therapeutic effect of the drug.
Compared to other existing analogues, GENFERON® LITE is also distinguished by the highest content of interferon1 (one dose of spray contains 50,000 IU of interferon α-2b), which ensures the creation of its higher concentration at the site of infection.
GENFERON® LIGHT spray is indicated for the first symptoms of ARVI, as well as for hypothermia during the seasonal increase in incidence or in case of contact with a patient (for prophylactic purposes).
Using GENFERON® LIGHT spray for therapeutic purposes at the first symptoms of a cold allows you to stop the development of symptoms of the disease or reduce their severity, speed up recovery and reduce the risk of infecting others. In addition, in the study, bacterial complications did not develop in patients treated with GENFERON® LITE ; in contrast to the group of patients receiving placebo3.
Among others, the following advantages of GENFERON® LIGHT :
ADVANTAGES OF THE COMPOSITION:
- a unique complex effect due to the properties of the drug components: antiviral - suppression of the activity and replication of a wide range of respiratory viruses (both influenza and ARVI); Moreover, the antiviral activity of interferon is not associated with a specific strain of influenza virus that has caused an epidemic increase in seasonal morbidity
- immunomodulatory – activation of the mechanisms of cellular and humoral immunity directed against influenza and ARVI viruses, as well as recognition and destruction of cells infected with viruses; restoration of the production of secretory immunoglobulin A by the nasal mucosa, which performs a protective function
- antibacterial – aimed at reducing the risk of bacterial superinfection and preventing the development of bacterial complications of influenza and ARVI
- anti-inflammatory – helps reduce the severity of the local inflammatory process, which usually accompanies rhinitis of viral etiology, reduces the degree of swelling of the mucous membrane and vascular permeability2, indirectly reducing the need for symptomatic vasoconstrictors
- reparative – acceleration of restoration and regeneration of the nasal mucosa damaged due to the activity of viruses and the inflammatory process
ADVANTAGES OF INTRANASAL USE:
- creation of a high concentration of active substances and targeted action directly at the “entrance gate” and the site of introduction of influenza and ARVI viruses (with intranasal use, a pronounced local antiviral and immunostimulating effect is achieved);
- implementation of antiviral activity and readiness for action from the moment of use of the drug;
- predominantly local effect: active substances are practically not absorbed from the surface of the nasal mucosa into the systemic bloodstream - as a result, there is no systemic undesirable effects on the body and minimal risk of side effects characteristic of antiviral and immunomodulatory drugs intended for oral administration (tablets, capsules, etc. );
- the absence of a negative effect on the gastrointestinal tract and the absence of exposure to aggressive enzymes of the gastrointestinal tract on the drug, in contrast to drugs taken orally;
- the possibility of using the drug in cases of nausea/vomiting, in case of impaired swallowing, in severe diseases of the digestive system, as well as in situations where the use of oral antiviral and immunotropic drugs is contraindicated (for example, during pregnancy)
ADVANTAGES OF SPRAY FORM OF RELEASE:
- uniform distribution of the drug over the entire surface of the mucous membrane due to fine spraying, as well as maximum penetration of the drug into the nasal cavity and nasal passages
- dosed spray nozzle ensures precise dosing of the drug with every use
- the activator pump ensures a stable jet force and solution supply with each press
- the rigid design of the bottle, equipped with a pump, ensures full use of the antiviral agent without residue
- spray form, convenient for use in both adults and active teenagers (1 spray = 1 press = 1 dose)
- compact bottle size
- economical - one bottle of antiviral spray contains 100 doses
- possibility of use during several episodes of colds or during several epidemic seasons - the shelf life is not limited from the moment the package is opened.
With the resumption of spray production, the GENFERON® LITE is able to satisfy the needs of a wide range of consumers of different ages who need to purchase drugs for the treatment of influenza and ARVI or their prevention:
- suppositories 125,000 IU - to combat colds in children from the first days of life to 7 years;
- suppositories GENFERON® LITE 250,000 IU – to combat colds in children over 7 years of age (this form of release can also be used in complex therapy of pregnant women with infectious and inflammatory diseases of the urogenital tract);
- GENFERON® LIGHT drops – for targeted local control of colds directly at the “entrance gate” of viral infection in children from the 1st month of life to 14 years;
- dosed spray GENFERON® LIGHT – for the treatment and prevention of influenza and ARVI in children over 14 years of age and adults, including pregnant women.
BIBLIOGRAPHY:
- Based on GRLS data as of August 2021.
- Alpenidze D.N., Borzanova M.V., Maklakova E.V., Romanova M.V., Chernyaeva E.V. Modern approaches to the treatment of ARVI in adults - experience of clinical use of interferon alpha nasal spray / D. N. Alpenidze [et al.]. - Practical Medicine, 2012. -N 6. - P.138-142.
Genferon light Suppositories, 10 pcs, 125000+0.005 IU+g
Directions for use and doses
The drug can be used both vaginally and rectally.
The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon Light is used in a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository. Recommended doses and treatment regimens:
● Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
● Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
● Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age: 1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
● Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Buy Genferon light vaginal/rectal suppositories 250t IU No. 10 in pharmacies
Genferon Light Buy Genferon Light in pharmacies
DOSAGE FORMS suppositories for vaginal or rectal administration 250000IU+5mg
MANUFACTURERS Biocad CJSC (Russia)
GROUP Antiviral - interferons
COMPOSITION Interferon alpha-2b, taurine.
INTERNATIONAL NON-PROPENTED NAME Interferon alpha-2b+Taurine
PHARMACOLOGICAL ACTION Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of β-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
INDICATIONS FOR USE For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.
CONTRAINDICATIONS Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of using the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.
SIDE EFFECTS Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur with the use of all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.
INTERACTION The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect
METHOD OF APPLICATION AND DOSAGE The drug can be used both vaginally and rectally. The method of administration, dosage and course duration depend on age, the specific clinical situation and are determined by the attending physician.
OVERDOSE In case of accidental simultaneous administration of more suppositories than prescribed by the doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
SPECIAL INSTRUCTIONS The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
STORAGE CONDITIONS Store at a temperature of 2 to 8 degrees. C. Keep out of the reach of children.
